DUBLIN, May 10, 2010 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/9d11d0/candidiasis_drug) has announced the addition of GlobalData's new report "Candidiasis - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
Candidiasis - Drug Pipeline Analysis and Market Forecasts to 2016, which provides the key data, information and analysis on the candidiasis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with candidiasis, a competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for the future market competition, and the key players in the candidiasis market.
The Candidiasis Market is Forecast to Grow at a Moderate Rate Between 2009 and 2016 Author forecasts the global candidiasis market to grow at 5.9% annually for the next seven years to reach $2,386m by 2016. It was valued at $1,592m in 2009.
This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009.
This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold.
Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.
Current Treatment Options with High Efficacy and Safety are Successful in Meeting Market Demand Author's analysis has found that the current competition in the candidiasis market is strong. The current candidiasis market landscape has more than 10 marketed products. The marketed products fall under three different classes: azoles, polyenes and echinocandins. Polyenes and azoles are some of the oldest classes of drugs being used in the treatment of different types of Candida infection. The drugs from these classes are quite successful in meeting the therapeutic needs of the market and have first rate efficacy and safety profiles. Moreover, these drugs are available in different dosage forms and have high patient compliance rates. Echinocandins are available in an intravenous dosage form and have medium to high efficacy in the treatment of serious Candida infections such as invasive candidiasis, esophageal candidiasis and systemic candidiasis. Furthermore, all the products are able to cure the Candida infection in most of the cases. Because the current treatment options offer high clinical and safety standards and successfully meet the market demands, the unmet need in the candidiasis market is low.
Opportunity and Unmet Need in the Candidiasis Market, 2010 Scope Annualized global candidiasis market revenues data from 2001 to 2009, forecast for seven years to 2016. Geographies covered in this report are the United States (the US), the United Kingdom (the UK), Italy, Spain, Germany, France and Japan. Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include monoclonal antibodies, cytochrome inhibitors, combination therapies, aminio acid sequences and antimicrobial peptides, selective immune response amplifiers, vaccines and protein synthesis inhibitors. Analysis of the current and future market competition in the global candidiasis market. The key market players covered Neutec Pharma PLC (a wholly owned subsidiary of Novartis AG), Novartis AG, Demegen, Inc. and Basilea Pharmaceutica Ltd. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future candidiasis market.
Reasons to buy Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the global candidiasis market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global candidiasis market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What's the next big thing in the global candidiasis market landscape? - Identify, understand and capitalize.
Key Topics Covered: Candidiasis: Market Characterization Global Candidiasis Market: Competitive Assessment Global Candidiasis Market: Pipeline Assessment Global Candidiasis Market: Implications for Future Market Competition Global Candidiasis Market: Future Players in Candidiasis Market Candidiasis Market: Appendix Companies Mentioned: Neutec Pharma PLC Novartis AG Demegen, Inc Basilea Pharmaceutica Ltd For more information visit http://www.researchandmarkets.com/research/9d11d0/candidiasis_drug SOURCE: Research and Markets CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2010 -0- INDUSTRY KEYWORD: Health
Pharmaceutical